Heart Failure With Preserved Ejection Fraction Clinical Trials
8 recruiting trials for Heart Failure With Preserved Ejection Fraction. Eligibility criteria explained in plain English.
TrialFinderData lists 8 Heart Failure With Preserved Ejection Fraction clinical trials drawn from ClinicalTrials.gov, all of which are currently recruiting participants.
Every phased trial in this set is Phase 3 (2 of the listed studies); the remaining records are observational or have no phase recorded on ClinicalTrials.gov.
Research is led by University Medical Center Goettingen (1), UConn Health (1), Pulnovo Medical (Wuxi) Co., Ltd. (1), among the most active sponsors registered for these trials.
The most frequently studied intervention is beta blocker discontinuation (other, 1 trial), followed by Pulmonary arterial denervation, Guideline-directed medical therapy (GDMT) for heart failure.
Track Heart Failure With Preserved Ejection Fraction trials
Subscribe for TrialFinderData updates by email. No spam, unsubscribe anytime.
Recruiting Trials
Clinical trial data sourced from the ClinicalTrials.gov registry, maintained by the National Library of Medicine. Always consult your doctor before considering any clinical trial.
Arterial Stiffening as a Predictor for Diastolic Cardiac Dysfunction and HFpEF
Patients at risk for developing heart failure with preserved ejection fraction (HFpEF) will undergo a structured clinical assessment, transthoracic echocardiography and pulse-wave...
Beta-blocker Discontinuation in Heart Failure With Preserved Ejection Fraction
This is a prospective pilot study to evaluate changes before and 4 weeks after beta-blocker withdrawal in 30 HFpEF patients.
A Trial to Evaluate the Safety and Efficacy of Pulmonary Artery Denervation for the Treatment of Pulmonary Hypertension...
It's a phase III, prospective, multicenter, randomized controlled trial to evaluate the safety and efficacy of the pulmonary artery denervation (PADN) for heart failure (HF)...
Spironolactone Initiation Registry Randomized Interventional Trial in Heart Failure With Preserved Ejection Fraction
Heart failure with preserved ejection fraction (HFPEF) is common and deadly but without therapy. Inconclusive studies such as TOPCAT (Treatment of Preserved Cardiac Function Heart...
Rifaximin and Cardiac Function in Patients with Heart Failure with Preserved Ejection Fraction
Single-center, double-blind, randomized, controlled intervention study of the effect of correction of bacterial overgrowth syndrome in the small intestine (SIBO) on cardiac...
Leg Heat Therapy in Heart Failure With Preserved Ejection Fraction
The objective of this pilot study is to establish evidence to support the validity of HT in improving skeletal muscle function and physical capacity of patients with HFpEF. Our...
Fiber Supplementation in Heart Failure With Preserved Ejection Fraction (HFpEF)
The study team is studying how increasing dietary fiber, specifically through adding potato starch to participant's diet, may impact the species of bacteria in participant's gut...
Cardiomyopathies and Heart Muscle Diseases: Cardiac Imaging in the Evaluation of Myocardial Fibrosis Transition
Heart scarring, also known as fibrosis, plays a major role in a lot of heart muscle abnormalities. These abnormalities of the heart muscle can lead to major issues such as...
Explore Other Conditions
Frequently Asked Questions
There are currently 8 clinical trials for Heart Failure With Preserved Ejection Fraction, with 8 actively recruiting participants. These include trials across all phases from early-stage Phase 1 to late-stage Phase 3.
To join a clinical trial for Heart Failure With Preserved Ejection Fraction, review the eligibility criteria on the trial detail pages, then talk to your doctor about whether a trial is right for you. Your doctor can help you evaluate the potential benefits and risks.
Phase 3 trials are large-scale studies that test whether a treatment is effective and monitor side effects. There are 2 Phase 3 trials for Heart Failure With Preserved Ejection Fraction, representing treatments closest to potential FDA approval.
Clinical trials follow strict safety protocols overseen by Institutional Review Boards (IRBs) and the FDA. Participants are monitored closely and can withdraw at any time. Always discuss risks and benefits with your healthcare provider before enrolling.
Trial data sourced from the ClinicalTrials.gov API. This site does not provide medical advice, always talk to your doctor about clinical trial participation.